Research.Patient.info

Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
This study is testing a new medicine, IPH6501, for people with a type of blood cancer called non-Hodgkin lymphoma. We want to see if it's safe, how well people tolerate it, and if it helps fight the cancer. This is an early stage trial.
France